CMS opens coverage analysis on MR angiography
This article was originally published in The Gray Sheet
Medicare agency opens 30-day comment period on Oct. 7 for an internally-generated national coverage analysis of magnetic resonance angiography (MRA), a magnetic resonance imaging procedure for visualization of blood flow and diseased vessels. CMS recently lifted the national non-coverage status for MRI for blood flow, leaving decisions on MRA in the hands of local Medicare contractors. The agency seeks comments on the long- and short-term clinical outcomes of MRA for indications that remain non-covered in the Medicare population. Comments are due Nov. 6, and CMS plans to issue a final decision by July 6, 2010
You may also be interested in...
Medicare agency finalizes its decision memo June 3 on magnetic resonance angiography, a specific application of magnetic resonance imaging used for blood flow determination, consolidating provisions under a single national coverage determination. The decision eliminates certain non-coverage language for MRA, but leaves most coverage decisions to the discretion of local contractors. CMS opened the coverage determination last October (1"The Gray Sheet" Oct. 12, 2009)
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.